10-Q: Surmodics Reports Q1 2025 Results, Impacted by Merger Costs and SurVeil DCB Revenue Decline

Surmodics' first quarter of fiscal year 2025 saw a net loss of $3.651 million, impacted by merger-related charges and a decrease in SurVeil DCB product sales.

Summary

• Surmodics reported a net loss of $3.651 million for the first quarter of fiscal year 2025, compared to a net loss of $0.786 million in the same period last year.
• Total revenue decreased by 2% year-over-year to $29.922 million, with a decline in both Medical Device and In Vitro Diagnostics segments.
• Medical Device product sales decreased by 15% due to lower SurVeil DCB sales, partially offset by growth in the Pounce thrombectomy platform.
• Performance coating royalties and license fees increased by 14%, driven by continued growth in customer utilization of Serene hydrophilic coating.
• SurVeil DCB license fee revenue was $1.3 million, and is expected to decline by $3.6 million in fiscal 2025 with no further revenue after March 31, 2025.
• In Vitro Diagnostics product sales decreased by 6% due to unfavorable order timing.
• Operating expenses increased, with selling, general, and administrative expenses rising by 21% due to $2.3 million in merger-related charges.
• The company expects product gross profit and gross margin to decline for the remainder of fiscal 2025 due to decreased SurVeil DCB revenue.
• The TRANSCEND pivotal clinical trial for the SurVeil DCB is expected to be completed in the second quarter of fiscal 2025.
• Cash used in operating activities was $7.9 million, and the company's cash and cash equivalents totaled $30.1 million as of December 31, 2024.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to increased losses, decreased revenue, and expected declines in key product lines. The merger costs and cash burn add to the negative sentiment, despite some positive developments in new product launches.

Positives

• Performance coating royalties and license fees saw a 14% increase, indicating strong demand for their Serene hydrophilic coating.
• The Pounce thrombectomy device platform continues to show growth, partially offsetting the decline in SurVeil DCB sales.
• The company completed limited market evaluations and commercially launched the Pounce LP Thrombectomy System and the Pounce Venous Thrombectomy System.
• The company received FDA 510(k) regulatory clearance for the Pounce XL Thrombectomy System and initiated limited market evaluations.
• The company completed limited market evaluations and commercially launched the Sublime microcatheter.

Negatives

• The company experienced a significant increase in net loss, from $0.786 million to $3.651 million year-over-year.
• Total revenue decreased by 2%, driven by declines in both Medical Device and In Vitro Diagnostics segments.
• Medical Device product sales decreased by 15%, primarily due to lower SurVeil DCB sales.
• The company expects a substantial decline in SurVeil DCB product and license fee revenue in fiscal 2025.
• Selling, general, and administrative expenses increased by 21%, largely due to merger-related charges.
• Cash used in operating activities was $7.9 million, indicating a cash burn.
• The company's cash and cash equivalents decreased by $10 million from the previous quarter.

Risks

• The company is facing a significant decline in revenue from SurVeil DCB products and license fees in fiscal 2025.
• The merger with BCE Parent, LLC is subject to regulatory approval and other closing conditions, which may not be satisfied.
• The company is incurring significant merger-related costs, impacting profitability.
• The company's reliance on a few major customers, such as Abbott and Medtronic, poses a risk to revenue stability.
• The company is experiencing ongoing operating losses and negative cash flow from operations.
• The company's ability to successfully commercialize new products, such as the Pounce and Sublime platforms, is crucial for future growth.
• The company is subject to risks related to the lengthy and costly new product development and regulatory approval processes.
• The company is exposed to increasing Euro currency risk with respect to its manufacturing operations in Ireland.

Future Outlook

The company anticipates a decline in SurVeil DCB product and license fee revenue in fiscal 2025. They expect to complete the TRANSCEND clinical trial in the second quarter of fiscal 2025. The company believes that existing cash, cash flow from operations, and the revolving credit facility will provide sufficient liquidity for fiscal 2025. They may seek additional sources of liquidity and capital resources in the future.

Management Comments

• Management believes their strategy of developing their own medical device products has increased, and will continue to increase, their relevance in the medical device industry.
• Management believes that the ease of use, intuitive design, and performance of their thrombectomy systems make these products attractive first-line treatment options for interventionalists.

Industry Context

The medical device industry is competitive, with companies constantly innovating and seeking regulatory approvals for new products. Surmodics' focus on vascular intervention devices and performance coatings aligns with the industry's trend towards minimally invasive procedures and advanced materials. The company's partnership with Abbott for the SurVeil DCB is a common strategy in the industry, leveraging established distribution networks. The company's direct sales strategy for its thrombectomy and radial access platforms is a move towards greater control over its commercialization efforts.

Comparison to Industry Standards

• Surmodics' revenue decline of 2% contrasts with some medical device companies that have reported growth in the same period, indicating potential challenges in their specific market segments.
• The increase in SG&A expenses due to merger-related costs is not uncommon during acquisition periods, but the magnitude of the increase may be higher than some industry peers.
• The company's focus on proprietary surface modification and drug-delivery coating technologies is a competitive advantage, but the success of these technologies depends on clinical outcomes and market adoption.
• The company's reliance on a few major customers is a common risk in the medical device industry, but the concentration of revenue with Abbott and Medtronic may be higher than some peers.
• The company's cash burn of $7.9 million in the quarter is a concern, and the company will need to manage its cash flow carefully to fund its operations and growth initiatives.
• Compared to companies like Medtronic and Abbott, Surmodics is a smaller player, and its financial results are more susceptible to fluctuations in product sales and market conditions.

Stakeholder Impact

• Shareholders are negatively impacted by the increased net loss and decreased revenue.
• Employees may be affected by the merger and potential restructuring.
• Customers may be impacted by changes in product availability and pricing.
• Suppliers may be affected by changes in the company's purchasing patterns.
• Creditors may be concerned about the company's increasing losses and cash burn.

Next Steps

• The company plans to complete the TRANSCEND pivotal clinical trial in the second quarter of fiscal 2025.
• The company will continue limited market evaluations of the Pounce XL Thrombectomy System in the first half of fiscal 2025.
• The company will continue to manufacture and ship commercial units of the SurVeil DCB to Abbott.
• The company will continue to invest in the commercialization of its vascular intervention device products.
• The company will continue to engage with the FTC with the goal of consummating the Merger in accordance with the definitive agreement for the Merger in the Companys second fiscal quarter ending March 31, 2025 if all the remaining closing conditions are satisfied.

Key Dates

Keywords

Surmodics, Medical Devices, In Vitro Diagnostics, Drug-Coated Balloon, Thrombectomy, Merger, Financial Results, Revenue, Net Loss, Operating Expenses, Regulatory Approval, Clinical Trials, Pounce, Sublime, Preside, Hydrophilic Coatings